Intent: To communicate Amgen's perspective on policy conditions that support innovation, investment, advanced manufacturing and high-value employment, and to contribute to transatlantic dialogue on life sciences competitiveness.
Details: Participation in a multi stakeholder life sciences roundtable on EU and Irish policy issues affecting the sector's competitiveness
Intent: To contribute to discussions, in the context of Ireland’s EU Presidency, on the EU Biotech Act and related health-policy initiatives and their potential contribution to life-sciences innovation, research, clinical trials and healthcare outcomes in Ireland and Europe.
Details: Engagements on life-sciences policy, innovation and competitiveness in Ireland and Europe
Attended and spoke at the EU Presidency Forum on 2nd of July 2026 - Event / ReceptionInformal discussions with MEPs and members of the European Committee of Regions at the EU Presidency Forum on July 2nd 2026 - Informal communicationParticipation in the Life Sciences Leadership event in the RCSI on June 18th 2026. - Event / Reception
Intent: Communicate priorities for the Irish financial services sector including Ireland's Presidency of the European Council, the EU Savings and Investment Union including Personal Investment Accounts, timely utilisation of the National Training Fund surplus to upskill the workforce, and highlight the importance of Ireland's Women in Finance Charter.
Details: Priorities for Ireland's financial services sector
Intent: Ensure an increased understanding of Apple's priorities and update on operational challenges and opportunities
Details: Meeting to discuss the EU simplification agenda, and implementation of EU legislation (EU Digital Markets Act, and Audiovisual Media Services Directive)
Intent: To support the competitiveness of the pharmaceutical industry in Europe and not therefore dilute or reduce RDP.::To include medical devices in Regulatory Sandboxes. ::Government to take strategic, integrated approach to address pharmaceutical industry concerns across diverse areas.
Details: EU Commission proposed revision of the EU General Pharmaceutical Legislation and related matters, with particular attention to intellectual property rights provisions, competitiveness and regulatory affairs.